Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non‐small cell lung cancer receiving EGFR‐TKI treatment
Background Lung cancer is the leading cause of cancer‐related deaths. Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are effective for advanced non‐small cell lung cancer (NSCLC) harboring EGFR mutations, some patients experience little or no response. The Glasgow p...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-08-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.13526 |
| _version_ | 1819206181660393472 |
|---|---|
| author | Norimitsu Kasahara Hisao Imai Ichiro Naruse Yusuke Tsukagoshi Mie Kotake Noriaki Sunaga Kyoichi Kaira Toshitaka Maeno Takayuki Asao Takeshi Hisada |
| author_facet | Norimitsu Kasahara Hisao Imai Ichiro Naruse Yusuke Tsukagoshi Mie Kotake Noriaki Sunaga Kyoichi Kaira Toshitaka Maeno Takayuki Asao Takeshi Hisada |
| author_sort | Norimitsu Kasahara |
| collection | DOAJ |
| description | Background Lung cancer is the leading cause of cancer‐related deaths. Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are effective for advanced non‐small cell lung cancer (NSCLC) harboring EGFR mutations, some patients experience little or no response. The Glasgow prognostic score (GPS) is an inflammation‐related score based on C‐reactive protein (CRP) and albumin concentrations, and has prognostic value in various cancer settings. This study aimed to evaluate whether GPS could predict response of NSCLC to EGFR‐TKIs. Methods This retrospective multicenter study evaluated patients with NSCLC harboring EGFR mutations who received EGFR‐TKI monotherapy from October 2006 to December 2016. GPS values were determined using CRP and albumin concentrations from before initiation of EGFR‐TKIs. The Kaplan‐Meier method and Cox proportional hazard models were used to evaluate progression‐free survival (PFS) and overall survival (OS). Results In 214 patients, 141, 43, and two patients had GPS values of 0, 1, and 2, respectively. The GPS independently predicted the efficacy of EGFR‐TKIs; good GPS (0–1) conferred significantly better PFS (hazard ratio [HR]: 0.59, 95% confidence interval [CI]: 0.38–0.96, P = 0.03) and OS (HR: 0.56, 95% CI: 0.33–0.96, P = 0.03). Multivariate analysis confirmed that a good GPS (0–1) independently predicted good PFS and OS among patients who had PS of 0–1. Good GPS (0–1) independently predicted good OS among patients receiving treatment in first‐line settings. Conclusions The GPS independently predicted the efficacy of EGFR‐TKIs for EGFR‐mutated NSCLC; however, further studies are needed to validate our findings. Key points Significant findings of the study Glasgow prognostic score (GPS) independently predicted the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) treatment for EGFR‐mutated NSCLC. What this study adds The findings presented in this paper will help to identify patients who will be expected to experience limited or no response to EGFR‐TKI treatment by using GPS. |
| first_indexed | 2024-12-23T05:03:31Z |
| format | Article |
| id | doaj.art-7d83077e9cd943e6b42f9d183f14d0f2 |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-12-23T05:03:31Z |
| publishDate | 2020-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-7d83077e9cd943e6b42f9d183f14d0f22022-12-21T17:59:09ZengWileyThoracic Cancer1759-77061759-77142020-08-011182188219510.1111/1759-7714.13526Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non‐small cell lung cancer receiving EGFR‐TKI treatmentNorimitsu Kasahara0Hisao Imai1Ichiro Naruse2Yusuke Tsukagoshi3Mie Kotake4Noriaki Sunaga5Kyoichi Kaira6Toshitaka Maeno7Takayuki Asao8Takeshi Hisada9Innovative Medical Research Center Gunma University Hospital Maebashi JapanDivision of Respiratory Medicine Gunma Prefectural Cancer Center Ota JapanDepartment of Respiratory Medicine Hidaka Hospital Takasaki JapanDepartment of Respiratory Medicine Gunma University Graduate School of Medicine Maebashi JapanDivision of Respiratory Medicine Gunma Prefectural Cancer Center Ota JapanDepartment of Respiratory Medicine Gunma University Graduate School of Medicine Maebashi JapanDepartment of Respiratory Medicine Comprehensive Cancer Center, International Medical Center, Saitama Medical University Saitama JapanDepartment of Respiratory Medicine Gunma University Graduate School of Medicine Maebashi JapanInnovative Medical Research Center Gunma University Hospital Maebashi JapanGraduate School of Health Sciences Gunma University Maebashi JapanBackground Lung cancer is the leading cause of cancer‐related deaths. Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are effective for advanced non‐small cell lung cancer (NSCLC) harboring EGFR mutations, some patients experience little or no response. The Glasgow prognostic score (GPS) is an inflammation‐related score based on C‐reactive protein (CRP) and albumin concentrations, and has prognostic value in various cancer settings. This study aimed to evaluate whether GPS could predict response of NSCLC to EGFR‐TKIs. Methods This retrospective multicenter study evaluated patients with NSCLC harboring EGFR mutations who received EGFR‐TKI monotherapy from October 2006 to December 2016. GPS values were determined using CRP and albumin concentrations from before initiation of EGFR‐TKIs. The Kaplan‐Meier method and Cox proportional hazard models were used to evaluate progression‐free survival (PFS) and overall survival (OS). Results In 214 patients, 141, 43, and two patients had GPS values of 0, 1, and 2, respectively. The GPS independently predicted the efficacy of EGFR‐TKIs; good GPS (0–1) conferred significantly better PFS (hazard ratio [HR]: 0.59, 95% confidence interval [CI]: 0.38–0.96, P = 0.03) and OS (HR: 0.56, 95% CI: 0.33–0.96, P = 0.03). Multivariate analysis confirmed that a good GPS (0–1) independently predicted good PFS and OS among patients who had PS of 0–1. Good GPS (0–1) independently predicted good OS among patients receiving treatment in first‐line settings. Conclusions The GPS independently predicted the efficacy of EGFR‐TKIs for EGFR‐mutated NSCLC; however, further studies are needed to validate our findings. Key points Significant findings of the study Glasgow prognostic score (GPS) independently predicted the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) treatment for EGFR‐mutated NSCLC. What this study adds The findings presented in this paper will help to identify patients who will be expected to experience limited or no response to EGFR‐TKI treatment by using GPS.https://doi.org/10.1111/1759-7714.13526BiomarkerEGFR‐TKIGlasgow prognostic scorenon‐small cell lung cancer |
| spellingShingle | Norimitsu Kasahara Hisao Imai Ichiro Naruse Yusuke Tsukagoshi Mie Kotake Noriaki Sunaga Kyoichi Kaira Toshitaka Maeno Takayuki Asao Takeshi Hisada Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non‐small cell lung cancer receiving EGFR‐TKI treatment Thoracic Cancer Biomarker EGFR‐TKI Glasgow prognostic score non‐small cell lung cancer |
| title | Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non‐small cell lung cancer receiving EGFR‐TKI treatment |
| title_full | Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non‐small cell lung cancer receiving EGFR‐TKI treatment |
| title_fullStr | Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non‐small cell lung cancer receiving EGFR‐TKI treatment |
| title_full_unstemmed | Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non‐small cell lung cancer receiving EGFR‐TKI treatment |
| title_short | Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non‐small cell lung cancer receiving EGFR‐TKI treatment |
| title_sort | glasgow prognostic score predicts efficacy and prognosis in patients with advanced non small cell lung cancer receiving egfr tki treatment |
| topic | Biomarker EGFR‐TKI Glasgow prognostic score non‐small cell lung cancer |
| url | https://doi.org/10.1111/1759-7714.13526 |
| work_keys_str_mv | AT norimitsukasahara glasgowprognosticscorepredictsefficacyandprognosisinpatientswithadvancednonsmallcelllungcancerreceivingegfrtkitreatment AT hisaoimai glasgowprognosticscorepredictsefficacyandprognosisinpatientswithadvancednonsmallcelllungcancerreceivingegfrtkitreatment AT ichironaruse glasgowprognosticscorepredictsefficacyandprognosisinpatientswithadvancednonsmallcelllungcancerreceivingegfrtkitreatment AT yusuketsukagoshi glasgowprognosticscorepredictsefficacyandprognosisinpatientswithadvancednonsmallcelllungcancerreceivingegfrtkitreatment AT miekotake glasgowprognosticscorepredictsefficacyandprognosisinpatientswithadvancednonsmallcelllungcancerreceivingegfrtkitreatment AT noriakisunaga glasgowprognosticscorepredictsefficacyandprognosisinpatientswithadvancednonsmallcelllungcancerreceivingegfrtkitreatment AT kyoichikaira glasgowprognosticscorepredictsefficacyandprognosisinpatientswithadvancednonsmallcelllungcancerreceivingegfrtkitreatment AT toshitakamaeno glasgowprognosticscorepredictsefficacyandprognosisinpatientswithadvancednonsmallcelllungcancerreceivingegfrtkitreatment AT takayukiasao glasgowprognosticscorepredictsefficacyandprognosisinpatientswithadvancednonsmallcelllungcancerreceivingegfrtkitreatment AT takeshihisada glasgowprognosticscorepredictsefficacyandprognosisinpatientswithadvancednonsmallcelllungcancerreceivingegfrtkitreatment |